BURLINGTON, ON, Sept. 25, 2012 /CNW/ - EKO INTERNATIONAL INC. (EKO) - EKNL- Pinksheets -- is pleased to announce that oeBin Ltd., of Burlington, ON, has been engaged by NeuroVasc Clinical Inc.(NCI), (a joint venture company owed 51 % by NeuroVasc Medical Inc.(NVMI) and 49% by EKO.), as NCI's sole distributor representative for FREMS equipment in the states of New York and Florida.
FREMS (Frequency Rhythmic Electrical Modulation System) equipment is used in the treatment of Peripheral Neuropathy (damage to nerves in extremities such as lower legs and feet causing an interruption in communication between the brain and parts of the body with damaged nerves).
With over 60 million diabetics in North America and 60% of them suffering from Peripheral Neuropathy, the need for this treatment is overwhelming.
Further news is expected to be released in the immediate future in respect of FREMS and EKO's involvement with the technology and expected corporate earnings as a result.
In order to clarify the present state of shareholdings in EKO, the company wishes to confirm that it fully complied with the April Order by the Chancery Court of Delaware to issue 2,926,224 free trading shares of EKO, bringing the number of issued and outstanding shares as of the date of this release from 28,756,746 to 31,682,970 and the current float of free trading shares as of the date of this release to 8,079,427.
EKO will be issuing a further 1,000,000 restricted shares to NeuroVasc Medical Inc. in consideration for EKO's participation in the NCI Joint venture which holds the exclusive rights to market FREMS equipment.
SOURCE: EKO INTERNATIONAL CORP.
For further information:
To contact the company by e-mail, please use [email protected]